 HOUSTON, Nov. 07, 2022 GLOBE NEWSWIRE -- Alaunos Therapeutics, Inc. Alaunos or the Company Nasdaq: TCRT, a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Companys human neoantigen T-cell receptor platform hunTR to expand its TCR Library. The data will be presented at the Society for Immunotherapy of Cancers SITC 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022. 